TGFBR1 and neoplasm: In summary, we have validated a new type of nanoparticle therapy, a synergistic VitE:SM nanoparticle composition, that offers the possibility of delivering chemotherapeutics like the TGF-βR1 inhibitor, LY2157299, with the objective of reprogramming TAMs of the tumor microenvironment to prevent liver metastasis in PDAC.